The Effects of Very Brief Exposure on PTSD in U.S. Combat Veterans (PTSD)

March 25, 2024 updated by: Bradley Peterson, Children's Hospital Los Angeles

The goal of this clinical trial is to develop a new behavioral treatment for U.S. combat veterans with post-traumatic stress disorder (PTSD), very brief exposure to combat-related stimuli. The main questions it aims to answer are:

  1. How does Very Brief Exposure (combat images and control everyday images) and Visible Exposure to combat stimuli affect brain activity and subjective fear ratings?
  2. To what extent are participants aware of the stimuli presented and tolerating the exposures?

All participants will view both very brief exposure and visible exposure to combat stimuli in the functional magnetic brain imaging (fMRI) scan. They will provide ratings of fear, awareness, and tolerability. Researchers will compare U.S. combat veterans with PTSD and healthy controls to confirm differences in brain region activation and ratings.

Study Overview

Status

Recruiting

Detailed Description

The prevailing treatment for Post-traumatic Stress Disorder (PTSD) is exposure: the confrontation of traumatic memories, in one form or another. Although exposure therapies are effective for combat related PTSD, confronting traumatic memories is inherently aversive, which may contribute to problems with patient acceptance. For example, trauma-focused PTSD therapies have higher dropout rates than non-trauma-focused therapies, and combat vets who drop out in real-world practice have more avoidance behaviors and greater arousal than those who remain in treatment. Study investigators have developed an alternative form of exposure that has been repeatedly shown to reduce behavioral, physiological, and self-reported fear symptoms in phobic persons without having them directly confront feared situations, and thus without causing them to experience emotional distress. In Very Brief Exposure (VBE), a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.

The goal is to develop a new behavioral treatment for U.S. combat veterans with PTSD, VBE to combat-related stimuli by:

  1. Identifying the unique effects of masked exposure to combat-related images (VBE) on the brain activity of U.S. combat veterans with PTSD. Study investigators will conduct a randomized controlled trial of VBE during fMRI scanning by manipulating awareness of exposure to combat-related stimuli, comparing the effects of VBE and (barely) visible exposure to these stimuli on the brain activity of 40 combat veterans with PTSD. Visible exposure to combat images is an active control condition that demonstrates the advantages of implicit exposure (VBE) in engaging extinction circuits and reducing fear responses. These advantages are not merely the consequences of exposure, but of how that exposure is delivered. The study thesis is that exposure is more effective, both in terms of circuit activity and fear responses, when delivered implicitly. Study investigators will manipulate the number of exposure sessions within each treatment group in order to identify the optimal number of sessions.
  2. Directly relating the effects of VBE on neural activity to those on behavioral symptoms of PTSD. Subjective fear levels will be measured. In statistical analyses, changes in brain activity induced by VBE will be directly related to its ensuing effects on all of these measures, and the neural mechanisms that mediate the reduction of PTSD symptoms will thereby be inferred.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • California
      • Los Angeles, California, United States, 90027
        • Recruiting
        • Brain Imaging Lab
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Patient Population

  • Males and females ages 18-50
  • Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) diagnosis of PTSD
  • Traumatic event is a combat-based experience (e.g., being injured, watching a buddy be killed)
  • Minimum score of 18 on the Combat Experience Scale (CES)
  • Minimum score of 3 or more on Primary Care (PC)-PTSD-5
  • Participants with other cooccurring psychiatric disorders (e.g., anxiety, ADHD) will be included to ensure a representative sample.

Healthy Population

• Males and Females, ages 18-50

Exclusion Criteria:

Patient Population

  • Treatment for PTSD, substance abuse, or mental health concerns in the past 6 months
  • 10 or more years since the combat trauma
  • Acute intoxication
  • Severe level of Substance Dependence (6 or more DSM-V symptoms)
  • Prior diagnosis of Autistic Spectrum Disorders
  • Current or past psychotic disorders or active psychotic symptoms
  • Current Bipolar I Disorder
  • Dementia
  • Neurological or serious medical conditions (e.g., stroke, epilepsy/ seizure disorder, cancer, Lupus, HIV+);
  • Traumatic brain injury

Healthy Population

  • Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make up w/ metallic content, transdermal medicinal patches that cannot be removed
  • Neurological or serious medical conditions (e.g., stroke, epilepsy/ seizure disorder, cancer, Lupus, HIV+);
  • Lifetime Diagnosis of PTSD, Tourette's Syndrome, Bipolar Disorder, Substance Dependence, Eating Disorder, Autism Spectrum Disorder, a psychotic disorder, Acute Stress Disorder
  • Lifetime history of traumatic event defined as a life-threatening event involving physical attack, guns, fire or explosion (i.e the kinds of traumatic events combat veterans are likely to experience)
  • Traumatic Brain Injury
  • Birth at less than 37 weeks gestational age
  • Claustrophobia
  • Anxiety Disorder, Mood Disorder, Substance Abuse Disorder, Adjustment Disorder in past 2 years
  • Treatment for mental health concern in past 2 years
  • Pregnant Females

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Image Exposure Arm
This within-subjects design study will have all participants view three types of exposure during fMRI scanning: VBE to combat images, VBE to masked everyday scenes (control), and conscious visible exposure to the same images (control).
In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Activation of Frontostriatal and Prefrontal Brain Regions to combat stimuli in PTSD
Time Frame: Day 2
A hypothesis-driven, group-level analysis will test brain activity, measured as Blood Oxygen Level Dependent (BOLD) response, in 4 regions of interest while minimizing Type II error.
Day 2

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fear induced by exposure to combat stimuli in PTSD in veteran group as measured by fear scale
Time Frame: Day 2
After each block of 10 combat stimuli trials, participants rate levels of fear on a 10-point, 1-10 visual analogue scale with these anchor point: "1 - No fear", "5 - Moderate but Tolerable Fear", and "10 - Very Intense Fear".
Day 2
Fear induced by exposure to combat stimuli in PTSD in healthy participants as measured by fear scale
Time Frame: Day 2
After each block of 10 combat stimuli trials, participants rate levels of fear on a 10-point, 1-10 visual analogue scale with these anchor point: "1 - No fear", "5 - Moderate but Tolerable Fear", and "10 - Very Intense Fear".
Day 2
Fear induced by exposure to combat stimuli in PTSD in veteran group as measured by fear scale
Time Frame: Days 3-7
After each block of 10 combat stimuli trials, participants rate levels of fear on a 10-point, 1-10 visual analogue scale with these anchor point: "1 - No fear", "5 - Moderate but Tolerable Fear", and "10 - Very Intense Fear".
Days 3-7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Bradley M Peterson, MD, Children's Hospital Los Angeles

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 22, 2024

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

January 1, 2026

Study Registration Dates

First Submitted

January 9, 2024

First Submitted That Met QC Criteria

January 18, 2024

First Posted (Actual)

January 23, 2024

Study Record Updates

Last Update Posted (Actual)

March 26, 2024

Last Update Submitted That Met QC Criteria

March 25, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Traumatic Stress Disorder

Clinical Trials on Very Brief Exposure to Combat Images

3
Subscribe